



You have downloaded a document from
RE-BUŚ
repository of the University of Silesia in Katowice

Title: Formation of stoichiometric and non-stoichiometric ionic liquid and cocrystal multicomponent phases of lidocaine with azelaic acid by changing counterion ratios

Author: Julija Zotova, Żaneta Wojnarowska, Brendan Twamley, Lidia Tajber

Citation style: Zotova Julija, Wojnarowska Żaneta, Twamley Brendan, Tajber Lidia. (2021). Formation of stoichiometric and non-stoichiometric ionic liquid and cocrystal multicomponent phases of lidocaine with azelaic acid by changing counterion ratios. "Journal of Molecular Liquids" (2021), Vol. 0, art. no. 117737, s. 1-33. DOI: 10.1016/j.molliq.2021.117737



Uznanie autorstwa - Licencja ta pozwala na kopiowanie, zmienianie, rozprowadzanie, przedstawianie i wykonywanie utworu jedynie pod warunkiem oznaczenia autorstwa.



UNIwersYTET ŚLĄSKI
W KATOWICACH



Biblioteka
Uniwersytetu Śląskiego



Ministerstwo Nauki
i Szkolnictwa Wyższego

Journal Pre-proofs

Formation of stoichiometric and non-stoichiometric ionic liquid and cocrystal multicomponent phases of lidocaine with azelaic acid by changing counterion ratios

Julija Zotova, Zaneta Wojnarowska, Brendan Twamley, Lidia Tajber

PII: S0167-7322(21)02462-4
DOI: <https://doi.org/10.1016/j.molliq.2021.117737>
Reference: MOLLIQ 117737


To appear in: *Journal of Molecular Liquids*

Received Date: 22 July 2021
Revised Date: 28 September 2021
Accepted Date: 29 September 2021

Please cite this article as: J. Zotova, Z. Wojnarowska, B. Twamley, L. Tajber, Formation of stoichiometric and non-stoichiometric ionic liquid and cocrystal multicomponent phases of lidocaine with azelaic acid by changing counterion ratios, *Journal of Molecular Liquids* (2021), doi: <https://doi.org/10.1016/j.molliq.2021.117737>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V.



1 **Formation of stoichiometric and non-stoichiometric ionic liquid and cocrystal multicomponent**
2 **phases of lidocaine with azelaic acid by changing counterion ratios**

3 **Authors:**

4 *Julija Zotova¹; Zaneta Wojnarowska²; Brendan Twamley³; Lidia Tajber^{1*}*

5 **Affiliations:**

6 ¹ School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, College Green, Dublin 2,
7 Ireland

8 ² Institute of Physics, University of Silesia, SMCEBI, 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland

9 ³ School of Chemistry, Trinity College Dublin, College Green, Dublin 2, Ireland

10 * Corresponding author, Lidia Tajber, School of Pharmacy and Pharmaceutical Sciences, Trinity College
11 Dublin, College Green, Dublin 2, Ireland. Tel: +35318962787. Email: ltajber@tcd.ie

12

13 **Abstract**

14 Tuning of physicochemical properties of ionic liquids and crystalline materials is a challenge that opens
15 up unlimited possibilities for expanding applications and controlling biological activity of
16 pharmaceutical multicomponent phases incorporating active pharmaceutical ingredients (APIs) with
17 counterions or coformers. In this work we have investigated the effect of changing lidocaine (LID) and
18 azelaic acid (AZE) ratios on the physicochemical properties of their corresponding multicomponent
19 systems using a thermodynamics-based approach. Microscopy, X-ray diffraction analysis, infrared
20 spectroscopy, nuclear magnetic resonance, and thermogravimetric analysis provided complimentary
21 characterisation. Mechanochemical synthesis of LID:AZE systems at a range of stoichiometries yielded
22 at least two distinct liquid phases and two distinct crystalline phases, one of which involved a unique
23 2:3 LID:counterion composition not observed previously. Furthermore, to the best of our knowledge
24 the formation of oligomeric ionic liquids involving dicarboxylic acids is also being reported for the first
25 time. This work highlights the need for a careful characterisation of multicomponent systems,
26 especially for pharmaceutical applications.

27

28

29 **Keywords:** lidocaine, azelaic acid, cocrystal, oligomeric ionic liquid, thermal analysis

30

32 1. Introduction

33 A number of interesting works have been published very recently raising awareness on the
34 continuum that exists between ionised and neutral pharmaceutical multicomponent systems.[1–3] A
35 change in preparation methods, temperature or stoichiometry can modulate the ionic character of
36 the system and yield different products as a result of complex interrelationship of kinetic and
37 thermodynamic aspects.[1,4–6] In particular, there are examples illustrating that distinct crystalline
38 structures obtained by varying stoichiometry of co-formers or counterions can tune the solid state
39 properties and performance of an active pharmaceutical ingredient (API).[7–9]

40 Although, the majority of the investigated pharmaceutically-relevant API multicomponent
41 systems are crystalline the rising significance of low-melting point solids or even liquid forms of such
42 systems has been recognised.[10–15] They include, but are not limited to ionic liquids, deep eutectic
43 mixtures, ionic cocrystals and oligomeric ionic liquids. Until recently, the intermolecular interactions
44 that play the major role in the classification of the liquid forms were mainly considered at simple 1:1
45 stoichiometric ratios and stoichiometries dictated by the counterion of choice.[16,17] On the other
46 hand, non-stoichiometric ratios were viewed as systems containing excess of either of the starting
47 materials.[18] However, it has been shown that mixtures of the counterions or the co-formers at
48 different stoichiometric ratios can potentially form distinct multicomponent systems not just in the
49 solid but also in the liquid state.[2,19]

50 Our previous work concentrated on a range of API-ILs incorporating lidocaine and medium-
51 chain dicarboxylic acids as the counterions. [20] LID is an aminoamide drug used as a local anaesthetic
52 with some antibacterial properties [21] and the molecule possesses one H-bond donor -NH group and
53 3 H-bond acceptor groups (**Scheme 1**). LID is practically insoluble in water and is formulated as a salt
54 to overcome the solubility constraints. The tertiary amine group has a pKa value of 7.9 rendering it a
55 weak base and most of the known LID salts undergo ionisation at this site.[22,23] However, in an
56 ionised form LID's membrane permeability is severely impeded.[24] Careful co-former or counterion
57 selection for a new LID multicomponent phase formation can greatly improve the API's performance

58 without undergoing chemical modification.[14,25,26] The LID ionic liquids (ILs) based on medium-
59 chain dicarboxylic acids were evaluated in terms of their thermal and dynamic behaviour supported
60 by crystallographic analysis in an attempt to devise a prediction tool for the structure–property
61 relationship. Alternating trends in morphology, melting points, glass transition temperatures and
62 crystallographic properties of the new phases were observed depending on the acid used. [20]

63 In this work we have investigated the influence of changing stoichiometry of LID and azelaic
64 acid (AZE), another medium-chain dicarboxylic acid on the physicochemical properties of their
65 corresponding multicomponent systems using a thermodynamics-based approach, which includes the
66 construction of the solid-liquid binary phase diagrams. Microscopy, X-ray diffraction analysis, infrared
67 spectroscopy, nuclear magnetic resonance, and thermogravimetric analysis provide complimentary
68 characterisation. The molecular structures of LID and the dicarboxylic acid investigated in the study
69 are shown in **Scheme 1**. AZE is a dicarboxylic acid commonly used as a topical bactericidal, antioxidant
70 and anti-inflammatory agent.[27–29] AZE is a weak acid with 2 carboxylic acid moieties at both ends
71 of the alkyl chain with pK_a values of 4.550 and 5.498. The differences in pK_a values (i.e. $\Delta pK_a = pK_a(\text{base})$
72 $- pK_a(\text{acid})$ are 3.35 and 2.4 meaning that both, salts and cocrystals could potentially be formed.[30]
73 Other known LID:dicarboxylic acid multicomponent systems reported to date were solely ionized
74 systems.[20,23,31] It was thus hypothesised that the LID:AZE combination would yield a similar
75 LID:dicarboxylic acid system. However, mechanochemical synthesis of LID:AZE systems yielded at least
76 two distinct liquid phases and two distinct solid phases, one of which involved a unique 2:3
77 LID:counterion composition not observed previously. Furthermore, to the best of our knowledge the
78 formation of oligomeric ionic liquids involving dicarboxylic acids have been reported for the first time.

79 **2. Materials and Methods**

80 **2.1 Materials**

81 LID (as a base) and azelaic acid (AZE) were purchased from Sigma-Aldrich (Ireland). Potassium
82 bromide for Infrared analysis was obtained from Honeywell Fluka and was dried in a vacuum oven at

83 room temperature prior to use. The purity of the compounds was at least 98%. All compounds were
84 used as obtained. Absolute ethanol used was of HPLC grade (Fisher Scientific, UK).

85 **2.2 Methods**

86 *2.2.1 Sample preparation*

87 LID and AZE was processed at a range of molar fractions between 0.1:0.9 to 0.9:0.1 (LID:AZE).
88 The constituents were accurately weighted with a Mettler Toledo MT5 microbalance (Mettler Toledo,
89 Switzerland) and ground in an agate mortar and pestle until homogenous mixtures were obtained. A
90 total of 200 mg of each sample was produced. A sample of each mixture was immediately analysed
91 and the remaining mixtures were transferred to 2 mL microcentrifuge tubes and kept at 4 °C until
92 further analysis.

93 *2.2.2 Polarised Optical Microscopy*

94 Prior to analysis LID and AZE were recrystallised from ethanol. A small crystal of each, LID and
95 AZE, were placed on a glass slide and were pushed together with the help of a needle. The glass slide
96 was examined using Olympus BX53 polarising optical microscope (Ireland) equipped with a U-POT
97 cross polarizer and a U-ANT analyser. Images were taken with an integrated Q IMAGING Fast 1394
98 camera (Olympus, Japan). The experiment was performed at room temperature.[20]

99 *2.2.3 Thermogravimetric Analysis (TGA)*

100 TGA was performed using Mettler TG50 measuring module coupled to a Mettler Toledo MT5
101 balance (Switzerland). Samples were weighed into an open aluminium pan (sample size approximately
102 5-11 mg) and heated from 25 °C to 200 °C at a rate of 10 K min⁻¹ under nitrogen as a purge gas. Upon
103 completion the samples were visually inspected and the thermograms were analysed for degradation
104 using Mettler Toledo STARe software (version 6.10).

105 *2.2.4 Differential Scanning Calorimetry (DSC)*

106 DSC measurements were carried out using a PerkinElmer Pyris1 Diamond DSC unit (USA). The
107 unit was refrigerated using a ULSP B.V. 130 cooling system (Netherlands). [20,32] Approximately 3-6
108 mg samples were weighed into aluminium pans and sealed. The samples were heated from 25 °C to
109 115 °C at the rate of 10 K min⁻¹ with nitrogen at a flow rate of 40 mL min⁻¹ used as the purge gas. The
110 samples were then supercooled to -60 °C at 300 K min⁻¹ cooling rate and a second heating cycle was
111 performed. Thermograms were analysed using Perkin Elmer Pyris software.

112 2.2.5 Fourier-Transform Infrared (FTIR) analysis

113 Prior to analysis LID:AZE mixtures at selected compositions were heated at 60 °C under
114 nitrogen gas for 30 min to remove moisture. The samples were prepared as KBr disks using direct
115 compression using a hydraulic press. Sample loading was approximately 1% (w/w). Infrared spectra
116 were recorded on Spectrum One spectrometer (Perkin Elmer, USA). A spectral range of 650-4000 cm⁻¹
117 and accumulation of 8 scans were used. Spectra was analysed using Spectrum v. 5.0.1 software.

118 2.2.6 Powder X-ray Diffraction (PXRD) analysis

119 The LID:AZE samples were prepared at room temperature and were kept at 4 °C prior to
120 analysis. PXRD was carried out at room temperature using Rigaku Miniflex II X-ray diffractometer
121 (Japan) equipped with Cu K α radiation (1.54 Å) X-ray source. The samples were scanned over a 2 θ
122 degrees range of 2–40° with a scan rate of 0.05 °/s. The tube voltage and tube current used were 30 kV
123 and 15 mA, respectively. [20]

124 2.2.7 Single Crystal X-ray Diffraction (SXRD)

125 Preparation of Phase 1 (2:1 LID:AZE cocrystal) - A sample of LID:AZE at equimolar composition
126 was heated until freely flowing liquid was obtained. The liquid sample was poured inside an NMR tube
127 and was kept in the fridge until crystals were observed.

128 Preparation of Phase 2 (2:3 LID:AZE ionic liquid) - Solidified polycrystalline powder at 1:1 molar
129 composition was obtained upon prolonged storage for 6 months at room temperature. A few crystals

130 were removed with a needle to be seeded onto a drop of liquefied 1:2 LID:AZE mixture on a glass slide
131 and kept at room temperature. Larger crystals of satisfactory quality for SXR analysis were harvested
132 after a week.

133 Data for 2:1 LID:AZE cocrystal and 2:3 LID:AZE salt samples were collected on a Bruker Apex
134 Kappa Duo using Cu K α radiation ($\lambda = 1.54178 \text{ \AA}$) using a MiTeGen microloop and at 100(2) K (Oxford
135 Cobra Cryosystem). Bruker APEX [33] software was used to collect, correct (Lorentz and polarization)
136 and reduce data. Absorption corrections were applied using SADABS.[34] The structure was solved
137 with the SHELXT [35] structure solution program using Intrinsic Phasing and refined with the SHELXL
138 [36] refinement package using Least Squares minimisation with Olex2[37], using the space group P2₁,
139 with Z = 2 for the formula unit, C₃₇H₆₀N₄O₆. Details of the data and refinement are given in **Table S1**.
140 All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were assigned to calculated
141 positions using a riding model with appropriately fixed isotropic thermal parameters; donor hydrogen
142 atoms (H9a, H9b, 18, H30) were located and refined with restraints (DFIX). The absolute configuration
143 was determined and confirmed by refining the Flack parameter as 0.3(2). CCDC 2098381 (Phase 1) and
144 2098382 (Phase 2) contain the supplementary crystallographic data for this paper. The data can be
145 obtained free of charge from The Cambridge Crystallographic Data Centre via
146 www.ccdc.cam.ac.uk/structures. The pXRD and SXR were compared using EXPO2014 [38] with a final
147 Le Bail refinement using the Pearson VII peak shape function with a w= 1.0/count weighting scheme.
148 Final agreement factors, 2:1 LID:AZE cocrystal : Rp = 10.017, Rwp = 14.605, Re = 4.926 and Chi2 =
149 8.791; 2:3 LID:AZE salt : Rp = 7.525, Rwp = 10.284, Re = 6.203, Chi2= 2.748.

150 2.2.8 Proton Nuclear Magnetic Resonance (¹H-NMR)

151 Crystalline 1:1 LID:AZE sample obtained upon prolonged storage at room temperature and 2:1
152 LID:AZE sample freshly prepared by neat grinding were dissolved in DMSO-d₆. ¹H-NMR measurements
153 were performed using Bruker Avance III 400 MHz spectrometer. The NMR spectra were analysed using
154 TopSpin 4.0.9 software. See **SI and Figure S1** for the ¹H-NMR peak assignment.

155 3. Results and discussion

156 3.1 Morphology of samples

157 The study was initiated by solvent-free neat grinding mechanochemical synthesis of the
158 LID:AZE systems at 0.1:0.9 – 0.9:0.1 molar compositions. Samples in the $\chi_{\text{LID}} = 0.33$ to 0.66 range
159 yielded semiliquid or soft solid (paste) samples at room temperature (**Figure 1a**). On the contrary,
160 systems at extreme molar LID or AZE molar fractions were solid powders. POM analysis was performed
161 to visually examine the process of liquefaction. The POM images in **Figure 1b** display the solid fusion
162 experiment where recrystallised LID and AZE were placed side by side and solid state reactivity was
163 observed. Crystalline regions that were in a direct contact started undergoing liquefaction at room
164 temperature almost immediately and a noticeable change was observed at $t = 10$ min. At $t = 7$ days
165 the entire interface has liquefied. This observation indicates that the melting point of the product of
166 the solid-state reaction is below room temperature and such behaviour is characteristic of a liquid, or
167 a “deep”, eutectic formation.[20,39,40] The remaining crystalline material that was not in a direct
168 contact has not been altered signifying the liquid eutectic does not diffuse nor dissolve parent
169 materials further. POM image in **Figure 1c** obtained at $t = 14$ days displays the formation of new
170 dendritic structures. These structures may suggest an irregular eutectic morphology of this phase
171 and/or a new phase formation.[41] Previously, POM demonstrated that LID reacted with glutaric acid
172 or pimelic acid showed a similar behaviour and these LID:dicarboxylic acid mixtures underwent solid
173 interdiffusion, while LID and suberic acid displayed true solid-state reactivity with the formation of a
174 solid eutectic at the interface. [20]

175 3.2 Thermal analysis

176 Starting materials LID and AZE as well as their mixtures at three different molar compositions
177 (2:1, 1:1 and ~~21:21~~ LID:AZE) were analysed for thermal degradation by TGA (**Figure 2a**). The results
178 showed that the weight loss upon heating up to 120 °C did not exceed 2%, see **Figure 2b and cb**.
179 Heating of the materials up to 120 °C generally results in dehydration or solvent evaporation. A very

180 slight increase in weight loss exhibited by the binary mixtures might be associated with increased
181 hygroscopicity of the samples following mixing. This observation is not unusual as it has been shown
182 that low melting systems generally display elevated hygroscopicity.[13] On the other hand, upon
183 heating to 200 °C the % weight loss is mainly caused by sample degradation. In this case LID and 2:1
184 LID:AZE underwent extensive degradation. However, upon addition of increased amount of AZE the
185 degradation was decreased. These results are also illustrated by the sample colour change after the
186 analysis. As seen in **Figure 2a** 2:1 LID:AZE mixture turned very dark brown as compared to lighter
187 brown colours of 1:1 and 1:2 samples.

188 DSC analysis of freshly prepared samples was carried out to study the phase change behaviour
189 of the LID:AZE systems at various molar compositions. **Figure 3a** presents a stack of DSC thermograms
190 of the first heating cycle at different LID:AZE molar compositions. LID and AZE exhibit sharp
191 endothermic peaks corresponding to their melting points of 69 °C and 106 °C, respectively. The
192 melting point depression of LID is observed and is indicated by a blue arrow as increasing molar
193 concentrations of AZE are added to the binary mixtures. A similar melting point depression is observed
194 in AZE (indicated by a brown arrow) with increasing LID content. This observation follows simple binary
195 phase behaviour as a result of decreasing purity of the starting components and has been observed in
196 numerous multicomponent systems previously.[42,43] In addition to the endothermic peaks
197 corresponding to the fusion events of the starting components the presence of new endothermic
198 peaks in LID:AZE mixtures indicates the formation of new crystalline arrangements. As visible from the
199 endothermic peaks in the yellow box the mechanochemical grinding of LID and AZE at high LID molar
200 concentrations leads to a new phase formation, referred to as Phase 1. At $\chi_{\text{LID}} = 0.6$ and 0.55 a melting
201 point depression of this Phase 1 is observed. The evolution of a double peak unique to 1:1 molar
202 composition infers the coexistence of two distinct crystalline arrangements. However, the second
203 peak is not easily discerned in samples with higher AZE content, probably due to the creation of
204 additional hydrogen bonds between the new crystalline structure and free diacid which leads to
205 further sample liquefaction. This phenomenon has been described previously in the formation of

206 deep eutectic mixtures (DEMs) and oligomeric ionic liquids.[44,45] It has been shown, but not
 207 generally recognised, that other forms of ionic liquids and DEMs can form at non-stoichiometric
 208 compositions and it is not just a 1:1 ionic liquid with excess carboxylic acid.[19,46–48] It has been
 209 proposed that such arrangement in the liquid phase can be described as $[BH^+][(\text{RCOO})_2H^-]$. [18] The
 210 inherent slow crystallisation kinetics of these systems hinders phase identification. In an attempt to
 211 curtail liquefaction samples in the range of $\chi_{\text{LID}} = 0.9$ to 0.2 were prepared and stored in the fridge for
 212 1 day prior to analysis. As indicated by a red box and arrow in **Figure 3b**, this sample treatment method
 213 enhanced new phase crystallisation, referred to as Phase 2.

214 Experimental T_m values were plotted as a function of LID molar fraction as seen in **Figure 4**.
 215 Dashed lines represent theoretical Schroeder van Laar solubility curves calculated using **Equation 1**,
 216 where T_{fus} (K) denotes the temperature of fusion and ΔH_{fus} (J mol^{-1}) denotes the enthalpy of fusion of
 217 the pure starting component, χ is the mole fraction of the pure starting component at a specified
 218 temperature T (K), and R is the gas constant.

$$219 \quad T = \left(\frac{1}{T_{fus}} - \frac{R \ln \chi}{\Delta H_{fus}} \right) \quad (\text{Eq. 1})$$

220 It is evident that the melting points of the parent components can be reasonably predicted at their
 221 corresponding extreme molar fractions. This agreement suggests that the unreacted starting
 222 components remain in the mixture in their unchanged form and no additional intermolecular
 223 interactions are depressing their corresponding T_m . However, the T_m of the parent components
 224 disappear at 0.3:0.7 – 0.6:0.4 LID:AZE molar compositions. This region is highlighted in **Figure 4**. This
 225 observation suggests new intermolecular interactions being created within the system and is
 226 corroborated by the appearance of melting events of Phase 1 and Phase 2. It is interesting to note that
 227 at the equimolar composition the melting events of these phases merge, thus creating a sensitive
 228 equilibrium where the identity of phase formation depends on fine sample preparation and storage
 229 variables.

230 Upon completion of the first heating step the samples at the entire range of compositions
231 were fast cooled at a nominal rate of 300 K/min and then subjected to a second heating step. **Figure**
232 **S2** presents a stack of second heating DSC thermograms which reveal the presence of glass transition
233 events (T_g) in LID:AZE mixtures which implies the ability of the systems to be supercooled. Pure starting
234 components do not exhibit T_g transitions as they crystallise during the cooling step. It is important to
235 note that the samples at the extreme LID and AZE compositions also undergo partial crystallisation
236 upon cooling and the T_g values of these systems are indicated by open star symbols in **Figure 4**. As can
237 be seen from **Figure 4**, there is a clear maximum in T_g at the equimolar composition of the acid and
238 the base. The observed extremum in T_g behaviour can be explained in terms of ionicity degree.
239 Previously, a marked increase in T_g has been correlated with the conversion of a given API into its
240 corresponding salt form e.g. hydrochloride, sulphate or phosphate.[44,49] Moreover, it has been
241 established that an increase in the T_g and melting point of classical aprotic ionic liquids is observed
242 when the electrostatic interactions start to dominate van der Waals forces.[50] Consequently, it is
243 expected that the supercooled equimolar LID:AZE system exhibits the most efficient proton transfer
244 and thus, comprises the highest concentration of ionised species.

245 *3.3 Investigation of ionicity in the supercooled state*

246 FTIR spectroscopy was employed to investigate the changes in intermolecular interactions
247 within the liquid systems as a function of LID:AZE molar composition (**Figure 5a**) to corroborate the
248 results obtained by thermal analysis. The systems were melted and analysed by FTIR immediately to
249 mimic the supercooled state investigated by the second DSC heating cycle. The clear T_g maximum
250 observed at the equimolar LID:AZE composition suggests the highest degree of ionisation and thus,
251 ionic liquid formation. One of the most prominent peaks observed corresponds to the carbonyl
252 stretching vibration and appears at 1664 cm^{-1} and 1694 cm^{-1} in LID and AZE spectra, respectively. The
253 magnified carbonyl region is presented as an inset in **Figure 5b** for clearer visualisation. However,
254 spectra obtained for the binary LID:AZE mixtures exhibit an additional carbonyl signal not attributable

255 to parent materials. This phenomenon is most clearly visible in the mixtures with higher LID content.
256 In the 2:1 LID:AZE supercooled sample the signal is found at 1717 cm^{-1} and its position is shifted to
257 1724 cm^{-1} in 1:1 supercooled LID:AZE mixture. In $\chi_{\text{LID}} = 0.4$ mixture the peak appears as a shoulder at
258 around 1717 cm^{-1} . The emergence of this peak may imply the formation of intermolecular H-bonds
259 between the -NH moiety of the LID's amide group and the carbonyl group of the AZE. As a result of -
260 NH group participating in the creation the new H-bond, the C=O bond is strengthened and a shift to
261 higher wavenumbers is observed. The greatest shift at the 1:1 composition suggests the strongest
262 amide-carbonyl H-bond formation, most probably due to formation of the homogenous 1:1 molecular
263 arrangement. This reasoning is corroborated by the complete disappearance of pure LID signal as a
264 result of being entirely used up in the 1:1 complex formation. Hence, giving rise to the observed T_g
265 maximum. On the other hand, AZE C=O signal persists in the spectrum, which can be explained by the
266 availability of 2 carbonyl groups and 1 being left unchanged. In addition, a prominent symmetric
267 stretching carboxylate ion peak at 1540 cm^{-1} appears in the spectra of mixtures, which provides an
268 indication that ionisation in the form of proton transfer between LID and AZE has taken place.

269 The decreased intensity and wavenumber of the amide N-H stretch at $3250 - 3170\text{ cm}^{-1}$ region
270 is caused by the dilution of LID in AZE and the formation of the H-bond (*vide supra*). A peak assignment
271 table is presented in **Table S2**. The presence of proton transfer in the 1:1 complex implies the
272 formation of an ionic liquid. The systems with the higher acid content, i.e. in the range $\chi_{\text{LID}} = 0.4$ to
273 0.33 possess a greater number of hydrogen bonds formed within the complexes and, as a result, the
274 systems are further liquefied. Depending on the arrangement of these additional H-bonds formed the
275 compositions may be classified as either oligomeric ionic liquids or deep eutectic mixtures.

276 3.4 Investigation of crystalline phases

277 PXRD analysis of the samples prepared as described in Section 2.2.1 revealed the formation
278 of a new crystalline phase at $\chi_{\text{LID}} = 0.5$ to 0.2 range of compositions, as seen in **Figure 6**. Melting of this
279 this new system, Phase 2, was first observed by thermal analysis (Figure 4). The PXRD pattern
280 corresponding to the new phase displays peaks that do not appear in the patterns on the parent

281 materials, such as at $2\theta = 6^\circ$, 11° , 14° and 16° . Low intensities of the peaks were observed due to the
282 sample being partially liquid. A peak at $2\theta = 6^\circ$ appears at a lower position as compared to the first
283 peaks of the parent materials signifying the formation of a larger crystal lattice.

284 An attempt to obtain a single crystal of Phase 2 has unexpectedly resulted in an identification
285 of a second, new crystalline phase, Phase 1. The PXRD pattern of this system is highlighted in red
286 colour in **Figure 6** and appears to be very similar to pure LID with some differences. In particular, the
287 2:1 system displays a peak at $2\theta = 8.4^\circ$ as compared to a peak at $2\theta = 8.2^\circ$ seen in LID, and displays
288 unique peaks at $2\theta = 11^\circ$, 18° , 24° , 27° and 28° . These peaks are also visible in the pattern of the χ_{LID}
289 = 0.5 mixture implying sample heterogeneity, where both new crystalline products coexist in
290 equilibrium.

291 *3.5 Effects of sample preparation and storage on systems speciation*

292 It is important to note the impact of method of sample preparation and storage conditions on
293 the LID:AZE complex formation. DSC analysis was performed using freshly ground samples without
294 preheating in order to capture any thermal transitions that occur at lower temperatures. For example,
295 a freshly ground 1:1 LID:AZE sample appears as a liquid (**Figure 1a**) with a small amount of solid
296 particles suspended within the liquid matrix. These particles were later identified as nucleation sites
297 for the formation of the new crystalline complexes (Phase 2) and DSC thermograms of these samples
298 allowed to capture their melting points. However, preheating 1:1 LID:AZE samples up to 60°C in an
299 oven destroyed these crystallisation nucleation sites resulting in a stable for at least 6 months ionic
300 liquid that did not crystallise on storage at room temperature. PXRD analysis of the freshly ground
301 samples allowed identification of the new crystalline structures being formed from these nucleation
302 sites, these crystals showed distinct PXRD patterns as seen in **Figure 6**. PXRD analysis of the equimolar
303 sample performed after preheating did not display any diffraction peaks and resulted in a disordered
304 "halo". The samples with the higher AZE content exhibited analogous behaviour. Therefore, it is

305 possible to conclude that LID:AZE molten mixtures form distinct ionic liquid phases at a range of
306 equimolar and non-stoichiometric ratios with greater acid content.

307 On the other hand, the base-rich 2:1 LID:AZE mixture was not as sensitive to environmental
308 variables. Crystalline Phase 2 was successfully obtained by both methods, neat grinding at room
309 temperature and co-melting parent components in an oven. Another important observation to note
310 is the equilibrium of the 2:1 and 1:1 complex formation in the LID:AZE equimolar mixtures. Depending
311 on the preparation and storage conditions different crystalline phases were observed and the
312 summary of the observations is presented in **Table 1**. The bulk synthesis of Phase 2 was not successful.
313 A range of seeding experiments were also attempted, where a polycrystalline impure Phase 2 was
314 seeded in a molten equimolar LID:AZE mixture, in a molten 1:2 LID:AZE mixture and in multiple organic
315 solvents. The impure Phase 2 contained a mixture of crystalline LID and both of the crystalline systems.
316 As a result, in most cases an identical impure polycrystalline material was obtained. These results can
317 be explained by the differences in the stability and solubility exhibited by these complexes, where the
318 least soluble and most stable system crystallising out first. This phenomenon has been identified and
319 investigated in other binary systems with LID [51] and other APIs [1,52,53]. However, seeding in a
320 molten acid-rich 1:2 mixture yielded a pure Phase 1 crystal with quality satisfactory for SXRD analysis.
321 The crystallisation work performed with LID:AZE mixtures was very challenging and before single
322 crystals were obtained a suspicion was raised that one of the crystalline phases might actually be a
323 degradation product. To check for sample degradation ¹H-NMR analysis was performed. The peak
324 assignment presented in **Figure S1** indicates that Phase 1 and Phase 2 differ in the solid state, but
325 degradation products were not observed in the ¹H-NMR spectra.

326 *3.6 Single Crystal XRD analysis*

327 Single crystals of the two distinct crystalline phases, Phase 1 and Phase 2, were obtained and
328 analysed. Phase 1, the 2:1 LID:AZE complex with a melting point of 47 °C and crystallising in a
329 monoclinic P2₁ space group was identified as a cocrystal. The theoretical PXRD pattern generated from
330 the SXRD data closely matched experimental PXRD patterns by visual inspection and a Le Bail

331 refinement with difference pattern shown in **Figure S3**. The asymmetric unit contains 2 LID molecules
332 and 1 AZE molecule held together by H-bonding interactions as seen in **Figure 7a**. The strongest H-
333 bonds are formed between the LID tertiary amine moiety and both AZE carboxylic groups with $d(D...A)$
334 = 2.583(3) and 2.603(3) Å. The formation of a cocrystal, rather than a salt is also evidenced by the AZE
335 carboxylic C-O bond length analysis. In salts, the deprotonation of a carboxylic acid results in a
336 carboxylate ion possessing two C-O bonds with similar D_{C-O} , i.e. the $\Delta D_{C-O} < 0.03$ Å, where ΔD_{C-O} is the
337 difference in length between the two C-O bonds within a carboxylate moiety. In cocrystals, neutral
338 carboxylic acids would possess two distinct C-O bonds with $\Delta D_{C-O} > 0.08$ Å.[54] The 2:1 LID:AZE complex
339 exhibits high ΔD_{C-O} values of 0.119 and 0.125 Å confirming cocrystal formation. The crystal structure is
340 further stabilised by the hydrogen-bonded NH...O heterosynthons ($d(D...A) = 2.900(3)$ and $2.932(3)$ Å)
341 formed between the LID amide moieties and further weak CH...O interactions ($d(D...A) = 3.243(3)$ Å).
342 The resulting structure forms zig-zag crystallisation patterns as seen in **Figure 7b**. See **Figure S5** and
343 **Table S3** for atom labels and a list of all hydrogen bonds present within the system.

344 Interestingly, despite the fact that the crystalline 2:1 LID:AZE system is a cocrystal, FTIR
345 analysis showed that the carboxylate ion peak was also visible in the supercooled mixture of the same
346 composition (**Figure 5**). This is due to the ability of the system to be partially liquified as indicated by
347 the presence of a T_g transition observed by DSC (**Figure 4**). Hence, the supercooled fraction of the
348 sample exhibits proton transfer due to increased molecular mobility.

349 The second crystalline phase, Phase 2, comprises a highly unusual 2:3 LID:AZE ratio and it is
350 characterised by a melting point onset of 50 °C. No other crystalline structures involving LID at such
351 ratio with other counterions or co-formers has been deposited in the CSD database to date. The
352 complex crystallises in a triclinic $P\bar{1}$ space group with 2 LID and 3 AZE molecules constituting an
353 asymmetric unit. Theoretical PXRD patterns generated from the SXRD data closely match
354 experimental PXRD patterns by visual inspection and a Le Bail refinement with difference pattern
355 shown in **Figure S4**. The crystalline structure is composed of 2 unionised AZE molecules, 1 doubly

356 ionised AZE anion and 2 ionised LID cations which are held together via a complex network of
357 hydrogen bonding interactions as seen in **Figure 8a-b**. The 2 LID molecules are ionised at the tertiary
358 amine sites via a proton transfer from both carboxyl moieties of a single AZE molecule. The complete
359 deprotonation of AZE is supported by C-O bond analysis, where the two carboxyl moieties possess
360 ΔD_{C-O} of 0.004 and 0.006 Å. The deprotonated carboxylate anions form hydrogen bonding interactions
361 with LIDH⁺ cations via all possible amine and amide H-bond donors, the strongest of which occurs
362 between the carboxylate anion and an amide moiety COO-...NH with $d(D...A) = 2.811(6)$ Å. The doubly
363 deprotonated AZE anion is further stabilised by H-bonds arising from unionised AZE carboxyl donors
364 with $d(D...A)$ distances ranging from 2.559(6) to 2.633(6) Å. See **Figure S6** and **Table S4** for atom labels
365 and a list of all hydrogen bonds present within the system. The structure is highly complex which
366 explains the great difficulty faced during crystallisation efforts.

367 The molecular arrangement resembles the bonding pattern characteristic of oligomeric ionic
368 liquids. However, all oligomeric ILs reported to date are formed from monocarboxylic acids and the
369 generalised molecular formula is generally accepted as $[BH^+][(\text{RCOO})_2H^-]$.^[18] The LID:AZE complex
370 presented in this paper is the first example of oligomeric ionic liquid composed of anions derived from
371 dicarboxylic acids. The molecular formula of the crystalline oligomeric complex may be written as
372 $[(BH^+)_2][(\text{HOOCR}(\text{COOH})_2)(\text{OOCR}(\text{COO})_2)^-]$. Due to the presence of a greater number of H-bonding donors
373 and resultant increased complexity of the potential ion patterns the molecular formula characterising
374 this crystalline complex may or may not be applicable to other dimeric or higher order oligomeric
375 anions and ionic liquids. It is also important to note that the crystalline structure corroborates the
376 interactions in the solid state and these findings support the presence of analogous interactions in the
377 liquid phase. Therefore, the 2:3 crystalline salt is the equivalent solid structure to the 2:3 oligomeric
378 ionic liquid in the liquid phase. In this context, the molecular formula of the 1:2 LID:AZE oligomeric
379 ionic liquid is $[BH^+][(\text{HOOCR}(\text{COO})_2H^-)]$.

380 **4. Conclusions**

381 This work has highlighted the importance of considering a range of stoichiometric ratios for
382 the formation of multicomponent systems incorporating acid-base pairs. Despite a series of equimolar
383 LID:dicarboxylic acid salts published previously we have demonstrated that LID and AZE binary
384 mixtures at various molar compositions can form a range of distinct multicomponent phases. This
385 approach allows for fine-tuning of physicochemical and crystallisation properties of a binary system
386 without altering its constituents. Neat grinding of LID and AZE has resulted in the formation of liquid
387 or semiliquid systems at the $\chi_{\text{LID}} = 0.33$ to 0.66 molar fractions, where 1:1 composition exhibited the
388 highest ionicity attributable to an ionic liquid formation. The greatest extent of liquefaction at $\chi_{\text{LID}} =$
389 0.4 was attributed to an oligomeric ionic formation, the crystal structure of which was solved to be a
390 2:3 oligomeric crystalline ionic liquid. To the best of our knowledge, such system is the first example
391 of an oligomeric ionic liquid composed of anions derived from dicarboxylic acids with a
392 $[(\text{BH}^+)_2][(\text{HOOCRCOOH})_2(\text{OOCRCOO})^2]$ general molecular formula. In addition, a crystal structure of
393 2:1 LID:AZE cocrystal was also successfully obtained. These results suggest that prediction of acid-base
394 multicomponent systems formation is more challenging when variable stoichiometric ratios are
395 considered. However, addressing the non-stoichiometric approach allows for a better understanding,
396 modification and visualisation of alternative forms of multicomponent phases.

397 Acknowledgements

398 This research was funded by Science Foundation Ireland, grant number 15/CDA/3602 and supported
399 by the European Cooperation on Science and Technology (COST) Action CA18112 "Mechanochemistry
400 for Sustainable Industry".

401 References

- 402 [1] D. Bernasconi, S. Bordignon, F. Rossi, E. Priola, C. Nervi, R. Gobetto, D. Voinovich, D. Hasa,
403 N.T. Duong, Y. Nishiyama, M.R. Chierotti, Selective Synthesis of a Salt and a Cocrystal of the
404 Ethionamide-Salicylic Acid System, *Cryst. Growth Des.* 20 (2020) 906–915.
405 doi:10.1021/acs.cgd.9b01299.

- 406 [2] M.E. Easton, K. Li, H.M. Titi, S.P. Kelley, R.D. Rogers, Controlling the Interface between Salts,
407 Solvates, Co-crystals, and Ionic Liquids with Non-stoichiometric Protic Azolium Azolates,
408 Cryst. Growth Des. 20 (2020) 2608–2616. doi:10.1021/acs.cgd.9b01733.
- 409 [3] H. Lengauer, D. Makuc, D. Šterk, F. Perdih, A. Pichler, T.T. Lušin, J. Plavec, Z. Časar, Co-
410 crystals, salts or mixtures of both? The case of tenofovir alafenamide fumarates,
411 Pharmaceutics. 12 (2020) 342. doi:10.3390/pharmaceutics12040342.
- 412 [4] D. Wiechert, D. Mootz, Molecular beside ionic: Crystal structures of a 1/1 and a 1/4 adduct of
413 pyridine and formic acid, Angew. Chemie - Int. Ed. 38 (1999) 1974–1976.
414 doi:10.1002/(sici)1521-3773(19990712)38:13/14<1974::aid-anie1974>3.0.co;2-f.
- 415 [5] S. Reddy Perumalla, C. Wang, Y. Guo, L. Shi, C.C. Sun, Robust bulk preparation and
416 characterization of sulfamethazine and saccharine salt and cocrystal polymorphs,
417 CrystEngComm. 21 (2019) 2089–2096. doi:10.1039/c8ce01076e.
- 418 [6] P. Stainton, T. Grecu, J. McCabe, T. Munshi, E. Nauha, I.J. Scowen, N. Blagden, First
419 Comparative Study of the Three Polymorphs of Bis(isonicotinamide) Citric Acid Cocrystals and
420 the Concomitant Salt 4-Carbamoylpyridinium Citrate Isonicotinamide, Cryst. Growth Des. 18
421 (2018) 4150–4159. doi:10.1021/acs.cgd.8b00597.
- 422 [7] B. Saikia, P. Bora, R. Khatioda, B. Sarma, Hydrogen Bond Synthons in the Interplay of
423 Solubility and Membrane Permeability/Diffusion in Variable Stoichiometry Drug Cocrystals,
424 Cryst. Growth Des. 15 (2015) 5593–5603. doi:10.1021/acs.cgd.5b01293.
- 425 [8] Z. Li, A.J. Matzger, Influence of Coformer Stoichiometric Ratio on Pharmaceutical Cocrystal
426 Dissolution: Three Cocrystals of Carbamazepine/4-Aminobenzoic Acid, Mol. Pharm. 13 (2016)
427 990–995. doi:10.1021/acs.molpharmaceut.5b00843.
- 428 [9] M. Samipillai, S. Rohani, The role of higher coformer stoichiometry ratio in pharmaceutical
429 cocrystals for improving their solid-state properties: The cocrystals of progesterone and 4-

- 430 hydroxybenzoic acid, *J. Cryst. Growth*. 507 (2019) 270–282.
- 431 doi:10.1016/j.jcrysro.2018.10.050.
- 432 [10] C. Agatemor, K.N. Ibsen, E.E.L. Tanner, S. Mitragotri, Ionic liquids for addressing unmet needs
433 in healthcare, *Bioeng. Transl. Med.* 3 (2018) 7–25. doi:10.1002/btm2.10083.
- 434 [11] R. Ferraz, L.C. Branco, C. Prudêncio, J.P. Noronha, Ž. Petrovski, Ionic liquids as active
435 pharmaceutical ingredients, *ChemMedChem*. 6 (2011) 975–985.
436 doi:10.1002/cmdc.201100082.
- 437 [12] J.L. Shamshina, P.S. Barber, R.D. Rogers, Ionic liquids in drug delivery, *Expert Opin. Drug Deliv.*
438 10 (2013) 1367–1381. doi:10.1517/17425247.2013.808185.
- 439 [13] A. Balk, U. Holzgrabe, L. Meinel, Pro et contra' ionic liquid drugs - Challenges and
440 opportunities for pharmaceutical translation, *Eur. J. Pharm. Biopharm.* 94 (2015) 291–304.
441 doi:10.1016/j.ejpb.2015.05.027.
- 442 [14] W.L. Hough, M. Smiglak, H. Rodríguez, R.P. Swatloski, S.K. Spear, D.T. Daly, J. Pernak, J.E.
443 Grisel, R.D. Carliss, M.D. Soutullo, J.H. Davis, Jr., R.D. Rogers, The third evolution of ionic
444 liquids: active pharmaceutical ingredients, *New J. Chem.* 31 (2007) 1429.
445 doi:10.1039/b706677p.
- 446 [15] A. Umerska, K. Bialek, J. Zotova, M. Skotnicki, L. Tajber, Anticrystal engineering of ketoprofen
447 and ester local anesthetics: Ionic liquids or deep eutectic mixtures?, *Pharmaceutics*. 12 (2020)
448 368. doi:10.3390/pharmaceutics12040368.
- 449 [16] B. Nuthakki, T.L. Greaves, I. Krodkiewska, A. Weerawardena, M.I. Burgar, R.J. Mulder, C.J.
450 Drummond, B. Nuthakki, T.L. Greaves, I. Krodkiewska, A. Weerawardena, M.I. Burgar, R.J.
451 Mulder, C.J. Drummond, Protic Ionic Liquids and Ionicity, *Aust. J. Chem.* 60 (2007) 21–28.
452 doi:10.1071/CH06363.
- 453 [17] W. Ogihara, H. Kosukegawa, H. Ohno, Proton-conducting ionic liquids based upon multivalent

- 454 anions and alkylimidazolium cations, *Chem. Commun.* (2006) 3637–3639.
455 doi:10.1039/B606186A.
- 456 [18] M.A.R. Martins, P.J. Carvalho, L.M.N.B.F. Santos, S.P. Pinho, J.A.P. Coutinho, The impact of
457 oligomeric anions on the speciation of protic ionic liquids, *Fluid Phase Equilib.* 531 (2021)
458 112919. doi:10.1016/j.fluid.2020.112919.
- 459 [19] K.M. Johansson, E.I. Izgorodina, M. Forsyth, D.R. Macfarlane, K.R. Seddon, Protic ionic liquids
460 based on the dimeric and oligomeric anions: [(AcO)_xHx-1]⁻, *Phys. Chem. Chem. Phys.* 10
461 (2008) 2972–2978. doi:10.1039/b801405a.
- 462 [20] J. Zotova, Z. Wojnarowska, B. Twamley, M. Paluch, L. Tajber, Green Synthesis of Lidocaine
463 Ionic Liquids and Salts: Mechanisms of Formation and Interactions in the Crystalline and
464 Supercooled States, *ACS Sustain. Chem. Eng.* 9 (2020) 18266–18276.
465 doi:10.1021/acssuschemeng.0c06811.
- 466 [21] J. Sedef Gocmen, U. Buyukkocak, O. Caglayan, A. Aksoy, In vitro antibacterial effects of topical
467 local anesthetics, *J. Dermatolog. Treat.* 19 (2008) 351–353.
468 doi:10.1080/09546630802050498.
- 469 [22] G.A. Neville, Z.R. Regnier, Hydrogen bonding in lidocaine salts. I. The NH stretching band and
470 its dependence on the associated anion, *Can. J. Chem.* 47 (1969) 4229–4235.
- 471 [23] D. Braga, L. Chelazzi, F. Grepioni, E. Dichiarante, M.R. Chierotti, R. Gobetto, Molecular salts of
472 anesthetic lidocaine with dicarboxylic acids: Solid-state properties and a combined structural
473 and spectroscopic study, *Cryst. Growth Des.* 13 (2013) 2564–2572. doi:10.1021/cg400331h.
- 474 [24] R. Pérez-Isidoro, F.J. Sierra-Valdez, J.C. Ruiz-Suárez, Anesthetic Diffusion Through Lipid
475 Membranes Depends on the Protonation Rate, *Sci. Rep.* 4 (2015) 7534.
476 doi:10.1038/srep07534.
- 477 [25] Y. Miwa, H. Hamamoto, T. Ishida, Lidocaine self-sacrificially improves the skin permeation of


- 478 the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid,
479 Eur. J. Pharm. Biopharm. 102 (2016) 92–100. doi:10.1016/j.ejpb.2016.03.003.
- 480 [26] P. Berton, K.R. Di Bona, D. Yancey, S.A. A Rizvi, M. Gray, G. Gurau, J.L. Shamshina, J.F. Rasco,
481 R.D. Rogers, Transdermal Bioavailability in Rats of Lidocaine in the Forms of Ionic Liquids,
482 Salts, and Deep Eutectic, ACS Med. Chem. Lett. 8 (2017) 44.
483 doi:10.1021/acsmchemlett.6b00504.
- 484 [27] A. Fitton, K.L. Goa, Azelaic Acid: A Review of its Pharmacological Properties and Therapeutic
485 Efficacy in Acne and Hyperpigmentary Skin Disorders, Drugs. 41 (1991) 780–798.
486 doi:10.2165/00003495-199141050-00007.
- 487 [28] J.P. Leeming, K.T. Holland, R.A. Bojar, The in vitro antimicrobial effect of azelaic acid, Br. J.
488 Dermatol. 115 (1986) 551–556. doi:10.1111/j.1365-2133.1986.tb05764.x.
- 489 [29] M.A. Sieber, J.K.E. Hegel, Azelaic acid: Properties and mode of action, Skin Pharmacol.
490 Physiol. 27 (2013) 9–17. doi:10.1159/000354888.
- 491 [30] J. Stoimenovski, E.I. Izgorodina, D.R. MacFarlane, Ionicity and proton transfer in protic ionic
492 liquids, Phys. Chem. Chem. Phys. 12 (2010) 10341–10347. doi:10.1039/c0cp00239a.
- 493 [31] Z. Wojnarowska, K.J. Paluch, E. Shoifet, C. Schick, L. Tajber, J. Knapik, P. Włodarczyk, K.
494 Grzybowska, S. Hensel-Bielowka, S.P. Verevkin, M. Paluch, Molecular origin of enhanced
495 proton conductivity in anhydrous ionic systems, J. Am. Chem. Soc. 137 (2015) 1157–1164.
496 doi:10.1021/ja5103458.
- 497 [32] Z. Wojnarowska, W. Smolka, J. Zotova, J. Knapik-Kowalczyk, A. Sherif, L. Tajber, M. Paluch,
498 The effect of electrostatic interactions on the formation of pharmaceutical eutectics, Phys.
499 Chem. Chem. Phys. 20 (2018) 27361–27367. doi:10.1039/c8cp05905e.
- 500 [33] Bruker, APEX, (2012).

- 501 [34] Bruker, SADABS, (2001).
- 502 [35] G.M. Sheldrick, Foundations and Advances SHELXT-Integrated space-group and crystal-
503 structure determination, *Acta Cryst. A* 71 (2015) 3–8. doi:10.1107/S2053273314026370.
- 504 [36] G.M. Sheldrick, Crystal structure refinement with SHELXL, *Acta Crystallogr. Sect. C Struct.*
505 *Chem.* C71 (2015) 3–8. doi:10.1107/S2053229614024218.
- 506 [37] O. V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, OLEX2: A complete
507 structure solution, refinement and analysis program, *J. Appl. Crystallogr.* 42 (2009) 339–341.
508 doi:10.1107/S0021889808042726.
- 509 [38] A. Altomare, C. Cuocci, C. Giacovazzo, A. Moliterni, R. Rizzi, N. Corriero, A. Falcicchio,
510 EXPO2013: A kit of tools for phasing crystal structures from powder data, *J. Appl. Crystallogr.*
511 46 (2013) 1231–1235. doi:10.1107/S0021889813013113.
- 512 [39] A.P. Abbott, G. Capper, D.L. Davies, R.K. Rasheed, V. Tambyrajah, Novel solvent properties of
513 choline chloride/urea mixtures, *Chem. Commun.* (2003) 70–71. doi:10.1039/B210714G.
- 514 [40] M.A.R. Martins, S.P. Pinho, J.A.P. Coutinho, Insights into the Nature of Eutectic and Deep
515 Eutectic Mixtures, *J. Solution Chem.* (123AD). doi:10.1007/s10953-018-0793-1.
- 516 [41] W. Kurz, D.J. Fisher, Dendrite growth in eutectic alloys: the coupled zone, *Int. Met. Rev.* 24
517 (1979) 177–204. doi:10.1179/IMTR.1979.24.1.177.
- 518 [42] G. Annat, M. Forsyth, D.R. MacFarlane, Ionic liquid mixtures-variations in physical properties
519 and their origins in molecular structure, *J. Phys. Chem. B.* 116 (2012) 8251–8258.
520 doi:10.1021/jp3012602.
- 521 [43] G.J. Maximo, R.J. B N Santos, P. Branda, J.S. S Esperanc, M.C. Costa, A.J. A Meirelles, M.G.
522 Freire, A.P. Coutinho, Generating ionic liquids from ionic solids: An investigation of the
523 melting behavior of binary mixtures of ionic liquids, *Cryst. Growth Des.* 14 (2014) 4270–4277.

- 524 doi:10.1021/cg500655s.
- 525 [44] J. Stoimenovski, P.M. Dean, E.I. Izgorodina, D.R. MacFarlane, Protic pharmaceutical ionic
526 liquids and solids: Aspects of protonics, *Faraday Discuss.* 154 (2012) 335.
527 doi:10.1039/c1fd00071c.
- 528 [45] K. Bica, J. Shamshina, W.L. Hough, D.R. MacFarlane, R.D. Rogers, Liquid forms of
529 pharmaceutical co-crystals: exploring the boundaries of salt formation, *Chem. Commun.* 47
530 (2011) 2267–2269. doi:10.1039/C0CC04485G.
- 531 [46] S.P. Kelley, A. Narita, J.D. Holbrey, K.D. Green, W.M. Reichert, R.D. Rogers, Understanding the
532 effects of ionicity in salts, solvates, co-crystals, ionic co-crystals, and ionic liquids, rather than
533 nomenclature, is critical to understanding their behavior, *Cryst. Growth Des.* 13 (2013) 965–
534 975. doi:10.1021/cg4000439.
- 535 [47] P. Berton, S.P. Kelley, H. Wang, A.S. Myerson, R.D. Rogers, Separate mechanisms of ion
536 oligomerization tune the physicochemical properties of n-butylammonium acetate: Cation-
537 base clusters vs. Anion-acid dimers, *Phys. Chem. Chem. Phys.* 19 (2017) 25544–25554.
538 doi:10.1039/c7cp04078d.
- 539 [48] K. Bica, R.D. Rogers, Confused ionic liquid ions - A “liquification” and dosage strategy for
540 pharmaceutically active salts, *Chem. Commun.* 46 (2010) 1215–1217. doi:10.1039/b925147b.
- 541 [49] K. Kaminski, E. Kaminska, K. Adrjanowicz, K. Grzybowiska, P. Włodarczyk, M. Paluch, A.
542 Burian, J. Ziolo, P. Lepek, J. Mazgalski, W. Sawicki, Dielectric relaxation study on tramadol
543 monohydrate and its hydrochloride salt, *J. Pharm. Sci.* 99 (2010) 94–106.
544 doi:10.1002/jps.21799.
- 545 [50] P. Sippel, P. Lunkenheimer, S. Krohns, E. Thoms, A. Loidl, Importance of liquid fragility for
546 energy applications of ionic liquids, *Sci. Rep.* 5 (2015) 1–8. doi:10.1038/srep13922.
- 547 [51] Y. Corvis, P. Négrier, M. Lazerges, S. Massip, J.M. Léger, P. Espeau, Lidocaine/ l -menthol

- 548 binary system: Cocrystallization versus solid-state immiscibility, *J. Phys. Chem. B.* 114 (2010)
549 5420–5426. doi:10.1021/jp101303j.
- 550 [52] E.A. Losev, E. V. Boldyreva, A salt or a co-crystal-when crystallization protocol matters,
551 *CrystEngComm.* 20 (2018) 2299–2305. doi:10.1039/c7ce02204b.
- 552 [53] Y. Yuan, L. Wang, D. Li, Z. Deng, H. Zhang, How Many Parameters Can Affect the Solid Form of
553 Cocrystallization Products in Mechanochemical Reactions? A Case Study, *Cryst. Growth Des.*
554 18 (2018) 7244–7247. doi:10.1021/acs.cgd.8b01320.
- 555 [54] S.L. Childs, G.P. Stahly, A. Park, The Salt-Cocrystal Continuum: The Influence of Crystal
556 Structure on Ionization State, (2007). doi:10.1021/mp0601345.
- 557
- 558

559 Graphical abstract



560

561 **Scheme 1.** Molecular structures of LID (left) and AZE (right). Yellow- H-bond donor and acceptor; blue-
 562 H-bond acceptor; red- carboxylic acid groups.

563

564 **Table 1.** Impact of preparation and storage variables on phase crystallisation in equimolar LID:AZE
 565 mixtures. * Phase 2 was only identified upon prolonged storage (about 3-6 months after sample
 566 preparation). ** Only once has this sample crystallised as Phase 2 in an NMR tube and this sample was
 567 used for SXR analysis.

568

569 **Figure 1. A:** Photographs of the LID:AZE samples immediately upon grinding. **B:** POM images of the
 570 solid fusion experiment. **C:** Interphase at a greater magnification showing dendritic formations.

571 **Figure 2. A:** Photographs of the TGA pans after analysis. **B:** TGA degradation profiles of LID, AZE and
 572 freshly ground binary mixtures. **C:** Values of % weight loss of LID, AZE and freshly ground binary
 573 mixtures upon heating up to 120 and 200 °C.

574 **Figure 3. A** - First heating DSC thermograms of the samples prepared at room temperature; **B** –
575 additional first heating DSC thermograms of the samples prepared at 4 °C. The red dotted line
576 indicates a sample prepared at room temperature and cooled at 4 °C.

577 **Figure 4.** Thermodynamic phase diagram, where T_m of Phase 1 (cocrystal) were obtained from samples
578 prepared at room temperature, while T_m of Phase 2 (ionic liquid) were obtained from samples
579 prepared at 4 °C. Dashed lines represent theoretical Schroeder van Laar solubility lines. Black dotted
580 lines indicate theoretical eutectic composition and T_m . Open star symbols indicate T_g values of the
581 samples that have undergone crystallisation on cooling.

582 **Figure 5. A:** FTIR spectra of the LID:AZE systems at various molar compositions. **B:** Inset with magnified
583 carbonyl region of the LID:AZE systems.


584 **Figure 6.** A stack of PXRD traces at the range of LID molar fractions χ_{LID} . The pattern highlighted in red
585 corresponds to Phase 1 and the pattern highlighted in orange corresponds to Phase 2.

586 **Figure 7. A:** Primary hydrogen bonding motif (dotted lines) in the 2:1 LID:AZE cocrystal (Phase 1).
587 Displacement shown at 50% probability. Only hydrogen atoms involved in the H-bonding motif are
588 shown. **B:** Packing diagram of 2:1 LID:AZE viewed normal to the a-axis. Dotted lines indicate hydrogen
589 bonding interactions. Displacement shown at 50% probability.

590 **Figure 8. A:** Primary hydrogen bonding motif (dotted lines) in the 2:3 LID:AZE IL (Phase 2).
591 Displacement shown at 50% probability. Only hydrogen atoms involved in the H-bonding motif are
592 shown. **B:** Packing diagram of 2:3 LID:AZE viewed normal to the a-axis. Dotted lines indicate hydrogen
593 bonding interactions. Displacement shown at 50% probability.

594

595


596 **Scheme 1.**603 **Table 1.**

		Preparation				
		Neat grinding, RT	Neat grinding, 4 °C	Co-melting at 60 °C	Seeding in molten 1:1 mixture	Seeding in molten 1:2 mixture
Storage	At RT	Impure polycrystalline	Not performed	Liquid	Impure polycrystalline	Phase 2
	At 4 °C	Impure polycrystalline	Impure polycrystalline *	Liquid**	Not performed	Not performed
	Under vacuum	Phase 1	Not performed	Phase 1	Impure polycrystalline	Not performed

604

605

606




607

608 **Figure 1.**

609

610


611



612

613 **Figure 2.**

614




615

616 **Figure 3.**

617

618




619

620 **Figure 4.**

621

622




623

624 **Figure 5.**

625


626



627

628 **Figure 6.**


629



630

631 **Figure 7.**

632



633

634 **Figure 8.**

635

636 **Highlights**

- 637
- First oligomeric ionic liquids made of lidocaine and a dicarboxylic acid was synthesised
- 638
- The composition of this ionic liquid was 2:3 lidocaine:azelaic acid
- 639
- A cocrystal phase was also isolated comprising 2:1 lidocaine:azelaic acid

640

641

642

Journal Pre-proofs

643 Julija Zotova: Conceptualization, Methodology, Formal analysis, Investigation, Writing - Original
644 Draft, Visualization.

645 Zaneta Wojnarowska: Conceptualization, Methodology, Formal analysis, Investigation.

646 Brendan Twamley: Methodology, Formal analysis, Investigation, Resources, Writing - Original Draft,
647 Visualization.

648 Lidia Tajber: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Writing -
649 Review & Editing, Visualization, Supervision, Project administration, Funding acquisition.

650 **Declaration of interests**

651

652 The authors declare that they have no known competing financial interests or personal
653 relationships that could have appeared to influence the work reported in this paper.

654

655 The authors declare the following financial interests/personal relationships which may be
656 considered as potential competing interests:

657

658

659

660

661

662